Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 25, Issue 12, 2005, Pages 2573-2579

  Grosskopf, Itamar ^a,b,c,h   Baroukh, Nadine ^d,e   Lee, Sung Joon ^f   Kamari, Yehuda ^g   Harats, Dror ^g   Rubin, Edward M ^d,e   Pennacchio, Len A ^d,e   Cooper, Allen D ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PALO ALTO MEDICAL FOUNDATION   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

^d LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^e DOE JOINT GENOME INSTITUTE   (United States)

^f Korea University   (South Korea)

^g SHEBA MEDICAL CENTER   (Israel)

^h TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Apoa5; Hypertriglyceridemia; Knockout; Lipolysis; Triglyceride rich lipoproteins

Indexed keywords

APOLIPOPROTEIN A5; APOLIPOPROTEIN C; APOLIPOPROTEIN E; CARBON 14; CHYLOMICRON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IODINE 125; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN RECEPTOR; TRIACYLGLYCEROL; TRITIUM; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; APOA5 PROTEIN, MOUSE; APOLIPOPROTEIN; CHOLESTEROL; LIPOPROTEIN; REMNANT LIKE PARTICLE CHOLESTEROL; REMNANT-LIKE PARTICLE CHOLESTEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIPOLYSIS; LIPOPROTEIN METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; CHEMISTRY; GENETICS; HYDROLYSIS; INSULIN RESISTANCE; LIVER; MALE; METABOLISM; MOUSE MUTANT; PARTICLE SIZE; PATHOPHYSIOLOGY; PHYSIOLOGY; SECRETION;

ANIMALS; APOLIPOPROTEINS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, VLDL; CHYLOMICRONS; HYDROLYSIS; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPOLYSIS; LIPOPROTEINS; LIVER; MALE; MICE; MICE, MUTANT STRAINS; PARTICLE SIZE; RECEPTORS, LDL; TRIGLYCERIDES;

EID: 33644794350     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000186189.26141.12     Document Type: Article

References (41)

1. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213-219.
2. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation. 1998;97:1029-1036.
3. Zannis VI, Chroni A, Kypreos KE, Kan HY, Cesar TB, Zanni EE, Kardassis D. Probing the pathways of chylomicron and HDL metabolism using adenovirus-mediated gene transfer. Curr Opin Lipidol. 2004;15: 151-166.
4. Shachter, Neil S. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol. 2001;12:297-304.
5. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM, Rubin EM. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science. 2001; 294:169-173.
6. van der Vliet HN, Sammels MG, Leegwater AC, Levels JH, Reitsma PH, Boers W, Chamuleau RA. Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J Biol Chem. 2001; 276:44512-44520.
7. Beckstead JA, Oda MN, Martin DD, Forte TM, Bielicki JK, Berger T, Luty R, Kay CM, Ryan RO. Structure-function studies of human apolipoprotein A-V: a regulator of plasma lipid homeostasis. Biochemistry. 2003;42:9416-9423.
8. Weinberg RB, Cook VR, Beckstead JA, Martin DD, Gallagher JW, Shelness GS, Ryan RO. Structure and interfacial properties of human apolipoprotein A-V. J Biol Chem. 2003;278:34438-34444.
9. Pennacchio LA, Rubin EM. Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice. Arterioscler ThrombVasc Biol. 2003;23:529-534.
10. Schaap FG, Rensen PC, Voshol PJ, Vrins C, van der Vliet HN, Chamuleau RA, Havekes LM, Groen AK, van Dijk KW. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem. 2004;279:27941-27947.
11. Fruchart-Najib J, Bauge E, Niculescu LS, Pham T, Thomas B, Rommens C, Majd Z, Brewer B, Pennacchio LA, Fruchart JC. Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem Biophys Res Commun. 2004;319:397-404.
12. Aalto-Setala K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, Walsh A, Ramakrishnan R, Ginsberg HN, Breslow JL. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest. 1992;90:1889-1900.
13. Cooper AD. The metabolism of chylomicron remnants by isolated perfused rat liver. Biochim Biophys Acta. 1977;488:464-474.
14. Redgrave TG. Formation of cholesterol ester rich particulate lipid during metabolism of chylomicrons. J Clin Invest. 1970;49:465-471.
15. de Faria E, Fong LG, Komaromy M, Cooper AD. Relative roles of the LDL receptor, the LDL receptor-like protein, and hepatic lipase in chylomicron remnant removal by the liver. J Lipid Res. 1996;37:197-209.
16. Kris-Etherton PM. Cooper AD. Studies on the etiology of the hyperlipemia in rats fed an atherogenic diet. J Lipid Res. 1980;21:435-452.
17. McFarlane AS. Efficient trace-labelling of proteins with iodine. Nature. 1958;182:53-54.
18. Yu KC, Jiang Y, Chen W, Cooper AD. Rapid initial removal of chylomicron remnants by the mouse liver does not require hepatically localized apolipoprotein E. J Lipid Res. 2000;41:1715-1727.
19. Yamada N, Havel RJ. Measurement of apolipoprotein B radioactivity in whole blood plasma by precipitation with isopropanol. J Lipid Res. 1986;27:910-912.
20. de Man FHA, de Beer F, van der Laarse A, Smelt AHM, Havekes LM. Lipolysis of very low density lipoproteins by heparan sulfate proteoglycane-bound lipoprotein lipase. J Lipid Res. 1997;38:2465-2472.
21. Siri P, Candela N, Zhang YL, Ko C, Eusufzai S, Ginsberg HN, Huang LS Post-transcriptional stimulation of the assembly and secretion of triglyceride-rich apolipoprotein B lipoproteins in a mouse with selective deficiency of brown adipose tissue, obesity, and insulin resistance. J Biol Chem. 2001;276:46064-46072.
22. Choi SY, Komaromy MC, Chen J, Fong LG, Cooper AD. Acceleration of uptake of LDL but not chylomicrons or chylomicron remnants by cells that secrete apoE and hepatic lipase. J Lipid Res. 1994;35:848-859.
23. Goldstein JL, Brown MS. Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. J Biol Chem. 1974;249:5153-5162.
24. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425-430.
25. Brunzell JD, Hazzard WR, Porte D Jr, Bierman EL. Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J Clin Invest. 1973;52: 1578-1585.
26. Kris-Etherton PM, Cooper AD. Studies on the etiology of the hyperlipemia in rats fed an atherogenic diet. J. Lipid Res. 1980;21:435-442.
27. Arbeeny CM, Rifici VA. The uptake of chylomicron remnants and very low density lipoprotein remnants by the perfused rat liver. J. Biol. Chem. 1984;259:9662-9666.
28. Greeve J, Altkemper I, Dieterich JH, Greten H, Windler E. Apolipoprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins. J Lipid Res. 1993;34:1367-1383.
29. Mahley RW, Innerarity TL, Rall SC Jr, Weisgraber KH. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res. 1984;25: 1277-1294.
30. Eisenberg S, Bilheimer DW, Levy RI, Lindgren FT. On the metabolic conversion of human plasma very low density lipoprotein to low density lipoprotein. Biochem Biophys Acta. 1973;326:361-377.
31. Jin W, Marchadier D, Rader DJ. Lipases and HDL metabolism. Trends Endocrinol Metab. 2002;13:174-178.
32. Coleman T, Seip RL, Gimble JM, Lee D, Maeda N. Semenkovich CF. COOH-terminal disruption of lipoprotein lipase in mice is lethal in homozygotes, but heterozygotes have elevated triglycerides and impaired enzyme activity. J Biol Chem. 1995;270:12518-12525.
33. Yu KC, Cooper AD. Postprandial lipoproteins and atherosclerosis. Front Biosci. 2001;6:D332-354.
34. Gianturco SH, Brown FB, Gotto AM Jr, Bradley WA. Receptor-mediated uptake of hypertriglyceridemic very low density lipoproteins by normal human fibroblasts. J Lipid Res. 1982;23:984-993.
35. Windler E, Greeve J, Robenek H, Rinninger F, Greten H, Jäckle S. Differences in the mechanisms of uptake and endocytosis of small and large chylomicron remnants by rat liver. Hepatology. 1996;24: 344-351.
36. de Silva HV, Lauer SJ, Wang J, Simonet WS, Weisgraber KH, Mahley RW, Taylor JM. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J Biol Chem. 1994;269:2324-2335.
37. Rensen PC, Herijgers N, Netscher MH, Meskers SC, van Eck M, van Berkel TJ. Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo. J Lipid Res. 1997;38:1070-1084.
38. van Barlingen HH, de Jong H, Erkelens DW, de Bruin TW. Lipoprotein lipase-enhanced binding of human triglyceride-rich lipoproteins to heparan sulfate: modulation by apolipoprotein E and apolipoprotein C. J Lipid Res. 1996;37:754-763.
39. Yu KC, Chen W, Cooper AD. LDL receptor-related protein mediates cell-surface clustering and hepatic sequestration of chylomicron remnants in LDLR-deficient mice. J Clin Invest. 2001;107:1387-1394.
40. Yu KC, Jiang Y, Chen W, Cooper AD. Evaluation of the components of the chylomicron remnant removal mechanism by use of the isolated perfused mouse liver. J Lipid Res. 1999;40:1899-1910.
41. Wilhelm MG, Cooper AD. Induction of atherosclerosis by human chylomicron remnants: a hypothesis. J Atheroscler Thromb. 2003;10: 132-139.